MyoKardia (MyoKardia) Float Percentage Of Total Shares Outstanding : 41.25% (As of May. 07, 2024)

View and export this data going back to 2015. Start your Free Trial

What is MyoKardia Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MyoKardia's float shares is 21.99 Mil. MyoKardia's total shares outstanding is 53.32 Mil. MyoKardia's float percentage of total shares outstanding is 41.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MyoKardia's Insider Ownership is 1.79%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MyoKardia's Institutional Ownership is 77.31%.

MyoKardia Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MyoKardia's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	21.99	/	53.32
	=	41.25%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MyoKardia (MyoKardia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyoKardia Inc (NAS:MYOK) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Sierra Point Parkway, Brisbane, CA, USA, 94005

Website

https://www.myokardia.com

MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Executives

Anastasios Gianakakos	director, officer: President and CEO	333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Denelle J Waynick	officer: General Counsel	C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary B Cranston	director	C/O VISA INC., P.O. BOX 8999, SAN FRANCISCO CA 94128-8999
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Wendy L Yarno	director
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jake Bauer	officer: Chief Business Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Taylor C. Harris	officer: Chief Financial Officer	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
William Fairey	officer: See Remarks	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Cynthia J Ladd	officer: General Counsel	C/O AGY THERAPEUTICS INC, 290 UTAH AVE, SOUTH SAN FRANCISCO CA 94080
Robert Scott Mcdowell	officer: Chief Scientific Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
June Lee	officer: EVP, Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017